Patents by Inventor Doris F. Cully
Doris F. Cully has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8163877Abstract: The present invention relates in part to isolated nucleic acid molecules (polynucleotides) which encode Dermacentor variabilis ligand gated ion channel proteins. The present invention also relates to recombinant vectors and recombinant hosts which contain a DNA fragment encoding D. variabilis LGIC/GluCl channels, substantially purified forms of associated D. variabilis channel proteins and recombinant membrane fractions comprising these proteins, associated mutant proteins, and methods associated with identifying compounds which modulate associated Dermacentor variabilis LGIC/GluCl, which will be useful as insecticides and acaricides.Type: GrantFiled: January 8, 2010Date of Patent: April 24, 2012Assignee: Merial LimitedInventors: Doris F. Cully, Yingcong Zheng
-
Patent number: 7915010Abstract: The present invention relates in part to isolated nucleic acid molecules (polynucleotides) which encode Rhipicephalus sanguineus glutamate gated chloride channels. The present invention also relates to recombinant vectors and recombinant hosts which contain a DNA fragment encoding R. sanguineus glutamate gated chloride channels, substantially purified forms of associated R. sanguineus glutamate gated chloride channels and recombinant membrane fractions comprising these proteins, associated mutant proteins, and methods associated with identifying compounds which modulate associated Rhipicephalus sanguineus glutamate gated chloride channels, which will be useful as insecticides.Type: GrantFiled: January 5, 2007Date of Patent: March 29, 2011Assignee: Merial LimitedInventors: Jeffrey W. Warmke, Youfeng Yang, Doris F. Cully, Michel J. Hamelin
-
Publication number: 20100184064Abstract: The present invention relates in part to isolated nucleic acid molecules (polynucleotides) which encode Dermacentor variabilis ligand gated ion channel proteins. The present invention also relates to recombinant vectors and recombinant hosts which contain a DNA fragment encoding D. variabilis LGIC/GluCl channels, substantially purified forms of associated D. variabilis channel proteins and recombinant membrane fractions comprising these proteins, associated mutant proteins, and methods associated with identifying compounds which modulate associated Dermacentor variabilis LGIC/GluCl, which will be useful as insecticides and acaricides.Type: ApplicationFiled: January 8, 2010Publication date: July 22, 2010Inventors: Doris F. Cully, Yingcong Zheng
-
Patent number: 7674586Abstract: The present invention relates in part to isolated nucleic acid molecules (polynucleotides) which encode Rhipicephalus sanguineus glutamate gated chloride channels. The present invention also relates to recombinant vectors and recombinant hosts which contain a DNA fragment encoding R. sanguineus glutamate gated chloride channels, substantially purified forms of associated R. sanguineus glutamate gated chloride channels and recombinant membrane fractions comprising these proteins, associated mutant proteins, and methods associated with identifying compounds which modulate associated Rhipicephalus sanguineus glutamate gated chloride channels, which will be useful as insecticides.Type: GrantFiled: January 5, 2007Date of Patent: March 9, 2010Assignee: Merial LimitedInventors: Jeffrey W. Warmke, Youfeng Yang, Doris F. Cully, Michel J. Hamelin
-
Patent number: 7655440Abstract: The present invention relates in part to isolated nucleic acid molecules (polynucleotides) which encode Dermacentor variabilis ligand gated ion channel proteins. The present invention also relates to recombinant vectors and recombinant hosts which contain a DNA fragment encoding D. variabilis LGIC/GluCl channels, substantially purified forms of associated D. variabilis channel proteins and recombinant membrane fractions comprising these proteins, associated mutant proteins, and methods associated with identifying compounds which modulate associated Dermacentor variabilis LGIC/GluCl, which will be useful as insecticides and acaracides.Type: GrantFiled: August 17, 2007Date of Patent: February 2, 2010Assignee: Merial LimitedInventors: Doris F. Cully, Yingcong Zheng
-
Patent number: 7645867Abstract: The present invention relates in part to isolated nucleic acid molecules (polynucleotides) which encode Dermacentor variabilis ligand gated ion channel proteins. The present invention also relates to recombinant vectors and recombinant hosts which contain a DNA fragment encoding D. variabilis LGIC/GluCl channels, substantially purified forms of associated D. variabilis channel proteins and recombinant membrane fractions comprising these proteins, associated mutant proteins, and methods associated with identifying compounds which modulate associated Dermacentor variabilis LGIC/GluCl, which will be useful as insecticides and acaracides.Type: GrantFiled: August 17, 2007Date of Patent: January 12, 2010Assignee: Merial LimitedInventors: Doris F. Cully, Yingcong Zheng
-
Patent number: 7541432Abstract: The present invention relates in part to isolated nucleic acid molecules (polynucleotides) which encode Rhipicephalus sanguineus glutamate gated chloride channels. The present invention also relates to recombinant vectors and recombinant hosts which contain a DNA fragment encoding R. sanguineus glutamate gated chloride channels, substantially purified forms of associated R. sanguineus glutamate gated chloride channels and recombinant membrane fractions comprising these proteins, associated mutant proteins, and methods associated with identifying compounds which modulate associated Rhipicephalus sanguineus glutamate gated chloride channels, which will be useful as insecticides.Type: GrantFiled: January 5, 2007Date of Patent: June 2, 2009Assignee: Merial LimitedInventors: Jeffrey W. Warmke, Youfeng Yang, Doris F. Cully, Michel J. Hamelin
-
Publication number: 20080286770Abstract: The present invention relates in part to isolated nucleic acid molecules (polynucleotides) which encode Rhipicephalus sanguineus glutamate gated chloride channels. The present invention also relates to recombinant vectors and recombinant hosts which contain a DNA fragment encoding R. sanguineus glutamate gated chloride channels, substantially purified forms of associated R. sanguineus glutamate gated chloride channels and recombinant membrane fractions comprising these proteins, associated mutant proteins, and methods associated with identifying compounds which modulate associated Rhipicephalus sanguineus glutamate gated chloride channels, which will be useful as insecticides.Type: ApplicationFiled: January 5, 2007Publication date: November 20, 2008Inventors: Jeffrey W. Warmke, Youfeng Yang, Doris F. Cully, Michel J. Hamelin
-
Patent number: 7267964Abstract: The present invention relates in part to isolated nucleic acid molecules (polynucleotides) which encode Dermacentor variabilis ligand gated ion channel proteins. The present invention also relates to recombinant vectors and recombinant hosts which contain a DNA fragment encoding D. variabilis LGIC/GluCl channels, substantially purified forms of associated D. variabilis channel proteins and recombinant membrane fractions comprising these proteins, associated mutant proteins, and methods associated with identifying compounds which modulate associated Dermacentor variabilis LGIC/GluCl, which will be useful as insecticides and acaracides.Type: GrantFiled: March 28, 2001Date of Patent: September 11, 2007Assignee: Merial LimitedInventors: Doris F. Cully, Yingcong Zheng
-
Patent number: 7244586Abstract: The present invention relates in part to isolated nucleic acid molecules (polynucleotides) which encode Drosophila melanogaster ligand-gated ion channel proteins. The present invention also relates to recombinant vectors and recombinant hosts which contain a DNA fragment encoding Drosophila ligand-gated ion channel proteins, substantially purified forms of associated Drosophila ligand-gated ion channel proteins and recombinant membrane fractions comprising these proteins, associated mutant proteins, and methods associated with identifying compounds which modulate associated Drosophila melanogaster ligand-gated ion channel proteins, which will be useful as insecticides.Type: GrantFiled: February 26, 2001Date of Patent: July 17, 2007Assignee: Merck & Co., Inc.Inventors: Doris F. Cully, Birgit Priest, Jeffrey Yuan, Yingcong Zheng
-
Patent number: 7220832Abstract: The present invention features Dermacentor variabilis GABA-gated chloride channel polypeptides and nucleic acids, and uses of such polypeptides and nucleic acids. D. variabilis is a widely distributed tick associated with different diseases. A preferred use of the present invention is to obtain compounds for preventing or treating a tick infestation.Type: GrantFiled: March 28, 2001Date of Patent: May 22, 2007Assignee: Merck & Co., IncInventors: Yingcong Zheng, Doris F. Cully, Steve W. Ludmerer
-
Patent number: 7202054Abstract: The present invention relates in part to isolated nucleic acid molecules (polynucleotides) which encode Rhipicephalus sanguineus glutamate gated chloride channels. The present invention also relates to recombinant vectors and recombinant hosts which contain a DNA fragment encoding R. sanguineus glutamate gated chloride channels, substantially purified forms of associated R. sanguineus glutamate gated chloride channels and recombinant membrane fractions comprising these proteins, associated mutant proteins, and methods associated with identifying compounds which modulate associated Rhipicephalus sanguineus glutamate gated chloride channels, which will be useful as insecticides.Type: GrantFiled: March 28, 2001Date of Patent: April 10, 2007Assignee: Merial LimitedInventors: Jeffrey W. Warmke, Youfeng Yang, Doris F. Cully, Michel J. Hamelin
-
Publication number: 20030229215Abstract: The present invention relates in part to isolated nucleic acid molecules (polynucleotides) which encode Rhipicephalus sanguineus glutamate gated chloride channels. The present invention also relates to recombinant vectors and recombinant hosts which contain a DNA fragment encoding R. sanguineus glutamate gated chloride channels, substantially purified forms of associated R. sanguineus glutamate gated chloride channels and recombinant membrane fractions comprising these proteins, associated mutant proteins, and methods associated with identifying compounds which modulate associated Rhipicephalus sanguineus glutamate gated chloride channels, which will be useful as insecticides.Type: ApplicationFiled: September 23, 2002Publication date: December 11, 2003Inventors: Jeffrey W. Warmke, Youfeng Yang, Doris F. Cully, Michel J. Hamelin
-
Publication number: 20030208041Abstract: The present invention features Dermacentor variabilis GABA-gated chloride channel polypeptides and nucleic acids, and uses of such polypeptides and nucleic acids. D. variabilis is a widely distributed tick associated with different diseases. A preferred use of the present invention is to obtain compounds for preventing or treating a tick infestation.Type: ApplicationFiled: September 25, 2002Publication date: November 6, 2003Inventors: Yingcong Zheng, Doris F. Cully, Steve W. Ludmerer
-
Publication number: 20030166144Abstract: Human, swine and rat growth hormone secretagogue receptors have been isolated, cloned and sequenced. Growth hormone secretagogue receptors are new members of the G-protein family of receptors. The growth hormone secretagogue receptors may be used to screen and identify compounds which bind to the growth hormone secretagogue receptor. Such compounds may be used in the treatment of conditions which occur when there is a shortage of growth hormone, such as observed in growth hormone deficient children, elderly patients with musculoskeletal impairment and recovering from hip fracture and osteoporosis.Type: ApplicationFiled: November 25, 2002Publication date: September 4, 2003Applicant: Merck & Co., Inc.Inventors: Joseph P. Arena, Doris F. Cully, Scott D. Feighner, Andrew D. Howard, Paul A. Liberator, James M. Schaeffer, Leonardus H. T. Van Der Ploeg
-
Publication number: 20030096984Abstract: The present invention relates in part to isolated nucleic acid molecules (polynucleotides) which encode Dermacentor variabilis ligand gated ion channel proteins. The present invention also relates to recombinant vectors and recombinant hosts which contain a DNA fragment encoding D. variabilis LGIC/GluCl channels, substantially purified forms of associated D. variabilis channel proteins and recombinant membrane fractions comprising these proteins, associated mutant proteins, and methods associated with identifying compounds which modulate associated Dermacentor variabilis LGIC/GluCl, which will be useful as insecticides and acaracides.Type: ApplicationFiled: September 23, 2002Publication date: May 22, 2003Inventors: Doris F. Cully, Yingcong Zheng
-
Patent number: 6531314Abstract: Human, swine and rat growth hormone secretagogue receptors have been isolated, cloned and sequenced. Growth hormone secretagogue receptors are new members of the G-protein family of receptors. The growth hormone secretagogue receptors may be used to screen and identify compounds which bind to the growth hormone secretagogue receptor. Such compounds may be used in the treatment of conditions which occur when there is a shortage of growth hormone, such as observed in growth hormone deficient children, elderly patients with musculoskeletal impairment and recovering from hip fracture and osteoporosis.Type: GrantFiled: June 3, 1998Date of Patent: March 11, 2003Assignee: Merck & Co., Inc.Inventors: Joseph P. Arena, Doris F. Cully, Scott D. Feighner, Andrew D. Howard, Paul A. Liberator, James M. Schaeffer, Leonardus H. T. Van Der Ploeg
-
Patent number: 6358701Abstract: To date, L-glutamate-gated chloride (GluCl) channels have been observed only in invertebrate organisms. Modulators of this channel (either agonists or antagoinists) will interfere with neurotransmission. For example, agents such as avermectins activate the GluCl, causing paralysis due to blocking of neurotranmitter release, resulting in death of the organism. Because GluCl channels are invertebreate specific, they are excellent targets for the discovery of novel insecticides, anthelminths and parasiticides that will display a marked safety profile because of the lack of mechanism based toxicity in vertebrate organisms. The present specification discloses isolation of a cDNA clone from the cat flea Ctenocephalides felis (CfGluCl-1) that encodes a L-glutamate-gated chloride channel. Heterologous expression of CfGluCl-1 cRNA in Xenopus oocytes results in robust expression of a L-glutamate-gated chloride current and the channel is activated and potentiated by avermectins.Type: GrantFiled: August 6, 1998Date of Patent: March 19, 2002Assignee: Merck & Co., Inc.Inventors: Jeffrey W. Warmke, Doris F. Cully, Adrian Etter, Philip S. Paress, Charles J. Cohen, Richard Brochu
-
Patent number: 6007998Abstract: A trans-activation assay for leptin is described. Leptin response elements are located proximal to a promoter, and the promoter region is operatively linked to a reporter gene. When leptin binds with the receptor, the reporter gene is transcribed.Type: GrantFiled: April 21, 1997Date of Patent: December 28, 1999Assignee: Merck & Co., Inc.Inventors: Charles I. Rosenblum, Leonardus H. T. Van Der Ploeg, Sajjad A. Qureshi, Doris F. Cully, John W. Hess, Michael R. Tota, Fang Chen
-
Patent number: 5693492Abstract: DNA encoding glutamate and avermectin-sensitive chloride channels have been cloned and characterized. The protein is capable of forming channels selectively opened with either avermectin or glutamate. The cDNA has been expressed in recombinant host cells which produce active recombinant protein. The recombinant protein is also purified from the recombinant host cells. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified. Receptor modulators active in the method disclosed herein are useful as ectoparasiticides, antiparasitic, anthelmenthic, acaracidal and insecticide agents.Type: GrantFiled: May 5, 1995Date of Patent: December 2, 1997Assignee: Merck & Co., Inc.Inventors: Doris F. Cully, Joseph P. Arena, Philip S. Paress, Ken K. Liu